Form 4: Sutro Biopharma Executive Barbara Leyman Reports Stock Option and RSU Grants

Barbara Leyman, Chief Business Development Officer at Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) on July 8, 2024.

Summary

• Barbara Leyman, Chief Business Development Officer of Sutro Biopharma, filed a Form 4 on July 10, 2024.
• The report details the grant of stock options and restricted stock units (RSUs) to Leyman on July 8, 2024.
• Leyman acquired options to purchase 125,000 shares of common stock at an exercise price of $3.04 per share.
• These options vest 25% on July 8, 2025, and then in equal monthly installments over the following three years, contingent upon continued service.
• Leyman also acquired 100,000 RSUs, each representing a contingent right to receive one share of Sutro Biopharma's common stock upon settlement.
• The RSUs vest in four equal annual installments beginning on July 8, 2025, also subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicitly negative aspects presented in the filing.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Granting stock options and RSUs to executives is a common practice in the biotechnology industry to incentivize performance and retain key personnel. This aligns with standard compensation practices in the sector.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice in the biotech industry for executive compensation.
• Comparable companies like Amgen, Gilead, and Biogen also utilize equity-based compensation to align executive incentives with shareholder value.
• The vesting schedules (25% after one year, then monthly or quarterly) are typical for these types of grants.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates